MET and lung carcinoma: In the current study, one of the MET exon 14 skipping mutation cases identified from a pulmonary carcinosarcoma [29], demonstrated such possibility and highlighted the necessity to broaden the screening scope for this mutation in other minority lung cancer subtypes.